

PDMR Application Submission Checklist

- Completed NCI PDMR request form

- Executed NCI MTA Agreement

- Copy of Purchase Order (if applicable)

Send the above completed documentation in a single e-mail to:
NCI_PDM_Repository@mail.nih.gov

Section 3: Billing Information

ACH/Wire and Check Payments Only: Made Out to the “<u>Leidos Biomedical Research.</u>”
Billing Contact Name: <input type="checkbox"/> Same as PI Above <input type="checkbox"/> Not Required; Intramural Maryland Campus Investigator
Billing Contact Phone:
Billing Contact E-mail (for Invoice):
Mailing Address:
PO# (only if required for purposes of invoicing)

Section 4: Acknowledgement of Understanding

The signature below indicates the Principal Investigator requesting the material understands the following:

- The recipients must maintain possession of any NCI Patient-Derived Models material at all times. Specifically, recipients may not transfer material to any other party without written approval by the NCI.
- NCI Patient-Derived Models material is human biological material and may contain infectious agents and therefore, will be handled appropriately.
- The recipients acknowledge/understand that PDMR TMA slides are not to be used for antibody optimization. This should be done prior to using antibodies on a TMA.
- Partial cost recovery remittance can be made by (i) electronic ACH/Wire payment (contact us for details) or (ii) mailed paper check made out to the “Leidos Biomedical Research.” These monies will then be transferred to the National Cancer Institute.

PI Signature:	Date:
----------------------	--------------

Section 5: TMA Selection and Research Plan

Summarize what assay(s) will be performed using each requested TMA slide(s) (e.g., IHC, IF). As part of the research plan, confirm that antibody optimization has already been performed on control tissues prior to use on the TMAs (if applicable). Notate if the results will be used to select NCI PDMM models for future research studies or if the TMA is an endpoint in itself. **IMPORTANT:** PDXs are composed of both human tumor tissue and murine stromal tissue. Antibody selection to minimize non-specific background staining (e.g., from anti-mouse secondaries) should be considered.

Project Title:
Research Plan:

Project Title:

Model Selection Criteria and Research Plan (maximum 2 pages):